Eric Coldwell
Stock Analyst at Baird
(3.55)
# 878
Out of 4,712 analysts
173
Total ratings
51.92%
Success rate
3.87%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IQV IQVIA Holdings | Maintains: Neutral | $213 → $212 | $199.99 | +6.01% | 15 | Dec 11, 2024 | |
| FTRE Fortrea Holdings | Downgrades: Neutral | $28 → $25 | $18.75 | +33.33% | 6 | Dec 6, 2024 | |
| MEDP Medpace Holdings | Maintains: Neutral | $349 → $354 | $342.69 | +3.30% | 16 | Nov 25, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $249 → $225 | $213.26 | +5.51% | 18 | Nov 20, 2024 | |
| MCK McKesson | Upgrades: Outperform | $531 → $688 | $579.13 | +18.80% | 17 | Nov 7, 2024 | |
| PINC Premier | Maintains: Neutral | $19 → $20 | $21.51 | -7.02% | 6 | Nov 6, 2024 | |
| AHCO AdaptHealth | Maintains: Outperform | $16 → $14 | $10.05 | +39.30% | 9 | Nov 6, 2024 | |
| OMI Owens & Minor | Maintains: Neutral | $19 → $14 | $12.72 | +10.06% | 14 | Nov 5, 2024 | |
| LH Labcorp Holdings | Maintains: Outperform | $282 → $289 | $229.49 | +25.93% | 12 | Oct 25, 2024 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $157 → $182 | $153.42 | +18.63% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $190 | $186.29 | +1.99% | 12 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $137 | $118.83 | +15.29% | 11 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $51 | $9.19 | +454.95% | 16 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $68.44 | -34.25% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $44.25 | +49.15% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.70 | +2,605.88% | 4 | Nov 10, 2017 |
IQVIA Holdings
Dec 11, 2024
Maintains: Neutral
Price Target: $213 → $212
Current: $199.99
Upside: +6.01%
Fortrea Holdings
Dec 6, 2024
Downgrades: Neutral
Price Target: $28 → $25
Current: $18.75
Upside: +33.33%
Medpace Holdings
Nov 25, 2024
Maintains: Neutral
Price Target: $349 → $354
Current: $342.69
Upside: +3.30%
ICON Public Limited Company
Nov 20, 2024
Maintains: Neutral
Price Target: $249 → $225
Current: $213.26
Upside: +5.51%
McKesson
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $579.13
Upside: +18.80%
Premier
Nov 6, 2024
Maintains: Neutral
Price Target: $19 → $20
Current: $21.51
Upside: -7.02%
AdaptHealth
Nov 6, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $10.05
Upside: +39.30%
Owens & Minor
Nov 5, 2024
Maintains: Neutral
Price Target: $19 → $14
Current: $12.72
Upside: +10.06%
Labcorp Holdings
Oct 25, 2024
Maintains: Outperform
Price Target: $282 → $289
Current: $229.49
Upside: +25.93%
Quest Diagnostics
Oct 23, 2024
Upgrades: Outperform
Price Target: $157 → $182
Current: $153.42
Upside: +18.63%
Sep 20, 2024
Maintains: Neutral
Price Target: $191 → $190
Current: $186.29
Upside: +1.99%
Aug 15, 2024
Maintains: Outperform
Price Target: $130 → $137
Current: $118.83
Upside: +15.29%
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $9.19
Upside: +454.95%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $68.44
Upside: -34.25%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $44.25
Upside: +49.15%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.70
Upside: +2,605.88%